<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>4basebio Plc — News on 6ix</title>
    <link>https://6ix.com/company/4basebio-uk-societas</link>
    <description>Latest news and press releases for 4basebio Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/4basebio-uk-societas" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835de8c78dffbe2df125310.webp</url>
      <title>4basebio Plc</title>
      <link>https://6ix.com/company/4basebio-uk-societas</link>
    </image>
    <item>
      <title>Lease of Manufacturing Facility</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/lease-of-manufacturing-facility</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/lease-of-manufacturing-facility</guid>
      <pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
      <description>4basebio PLC is expanding its operations with the lease of a new 26,500 square foot innovation hub and manufacturing facility in Cambridge, UK, expected to be operational by late summer 2026. This expansion, which includes 7,500 square feet of specialized laboratory space and an additional 7,500 square feet for future growth, is designed to meet the increasing demand for high-quality synthetic DNA crucial for next-generation therapeutics such as mRNA vaccines, gene and cell therapies, and genome</description>
    </item>
    <item>
      <title>Appointment of COO</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/appointment-of-coo-6</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/appointment-of-coo-6</guid>
      <pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
      <description>4basebio PLC has appointed Scott Lorimer as Chief Operating Officer to support its accelerated growth strategy and transition from an R&amp;D-driven to a commercial organization. Lorimer brings approximately 30 years of experience in bioprocess development and commercial manufacturing of biologics and cell and gene therapies, with a proven track record in scaling operations and obtaining regulatory approval for GMP manufacturing facilities. He will oversee the scaling of the company&apos;s synthetic DNA </description>
    </item>
    <item>
      <title>4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/4basebio-strengthens-commercial-leadership-promoting-christine-wolosin-to-chief-commercial-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/4basebio-strengthens-commercial-leadership-promoting-christine-wolosin-to-chief-commercial-officer</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 GMT</pubDate>
      <description>Seasoned biotechnology commercial leader will drive global growth strategy Commercial team further bolstered by promotions of James Vang and Jennifer Gelman to VP, Business Development and VP, Marketing, respectively CAMBRIDGE, UK, 3 March 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice P</description>
    </item>
    <item>
      <title>Leadership Changes</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/leadership-changes</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/leadership-changes</guid>
      <pubDate>Tue, 10 Feb 2026 07:00:00 GMT</pubDate>
      <description>4basebio PLC has appointed Dr. Amy Walker as its new Chief Executive Officer, succeeding founder Dr. Heikki Lanckriet, who will lead a new entity focused on the Hermes nanoparticle platform and remain on the Board. David Roth will also step down as Chief Financial Officer to join the new venture. Dr. Walker, previously Chief Operating Officer, is expected to drive an accelerated commercial growth strategy, focusing on the synthetic DNA market as customers increasingly seek alternatives to plasmi</description>
    </item>
    <item>
      <title>Synthetic opDNA® utilised in Phase I/II US cl...</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/synthetic-opdnar-utilised-in-phase-iii-us-cl</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/synthetic-opdnar-utilised-in-phase-iii-us-cl</guid>
      <pubDate>Mon, 27 Oct 2025 07:00:00 GMT</pubDate>
      <description>4basebio PLC announced that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II US clinical trials with an mRNA product developed using 4basebio’s proprietary opDNA® template, following FDA Investigational New Drug (IND) approval. The supply agreement with the partner was signed in April 2024. This milestone follows 4basebio receiving GMP certification from the UK’s MHRA in April 2025 for its late-phase manufacturing facility. The opDNA® template supports mRNA invitro </description>
    </item>
    <item>
      <title>Result of Extraordinary General Meeting</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/result-of-extraordinary-general-meeting-1</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/result-of-extraordinary-general-meeting-1</guid>
      <pubDate>Fri, 10 Oct 2025 10:30:00 GMT</pubDate>
      <description>4basebio PLC announced that all resolutions proposed at its Extraordinary General Meeting held on October 10, 2025, were duly passed.

                Disclaimer*</description>
    </item>
    <item>
      <title>Director Dealing</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/director-dealing-6</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/director-dealing-6</guid>
      <pubDate>Tue, 30 Sep 2025 15:20:00 GMT</pubDate>
      <description>On September 30, 2025, 4basebio PLC announced that CEO Dr. Heikki Lanckriet purchased 2,000 ordinary shares on September 29, 2025. The aggregated purchase price was 749 pence. Following this transaction, Dr. Lanckriet&apos;s total shareholding is 1,119,688 shares, representing 7.21% of the company&apos;s issued share capital. The 2,000 shares acquired represent approximately 0.01% of the company&apos;s issued share capital, which comprises 15,538,518 ordinary shares. The transactions took place on the London S</description>
    </item>
    <item>
      <title>Half-year Report</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/half-year-report-61</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/half-year-report-61</guid>
      <pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
      <description>4basebio PLC reported revenues of £1.2 million for the first half of 2025, a 25% increase compared to the full year 2024. The company holds cash balances of £26.1 million at the period&apos;s end. However, the company experienced a loss for the period of £7.8 million, which is greater than the £5.7 million loss in H1 2024, due to strategic investments. Net cash outflow from operating activities was £8.2 million, compared to £5.1 million in the first half of the previous year. The company&apos;s non-curren</description>
    </item>
    <item>
      <title>Employee Long Term Incentive Plan and Issue o...</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/employee-long-term-incentive-plan-and-issue-o</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/employee-long-term-incentive-plan-and-issue-o</guid>
      <pubDate>Tue, 22 Jul 2025 06:00:00 GMT</pubDate>
      <description>Employee Long Term Incentive Plan and Issue o....</description>
    </item>
    <item>
      <title>Director Appointment, Board Change</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/director-appointment-board-change</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/director-appointment-board-change</guid>
      <pubDate>Tue, 08 Jul 2025 09:30:00 GMT</pubDate>
      <description>Director Appointment, Board Change.</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/holdings-in-company-169</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/holdings-in-company-169</guid>
      <pubDate>Thu, 03 Jul 2025 06:00:00 GMT</pubDate>
      <description>Holding(s) in Company.</description>
    </item>
    <item>
      <title>4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/4basebio-introduces-new-branding-to-reflect-next-phase-of-growth-enabling-development-of-advanced-genetic-therapies</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/4basebio-introduces-new-branding-to-reflect-next-phase-of-growth-enabling-development-of-advanced-genetic-therapies</guid>
      <pubDate>Tue, 01 Jul 2025 08:30:00 GMT</pubDate>
      <description>CAMBRIDGE, England, July 01, 2025--4basebio PLC (AIM: 4BB) (&quot;4basebio&quot;), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/result-of-agm-140</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/result-of-agm-140</guid>
      <pubDate>Fri, 27 Jun 2025 17:05:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Exercise of Options</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/exercise-of-options-4</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/exercise-of-options-4</guid>
      <pubDate>Wed, 25 Jun 2025 06:00:00 GMT</pubDate>
      <description>Exercise of Options.</description>
    </item>
    <item>
      <title>Final Results and Notice of AGM</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/final-results-and-notice-of-agm-1</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/final-results-and-notice-of-agm-1</guid>
      <pubDate>Tue, 27 May 2025 06:00:00 GMT</pubDate>
      <description>Final Results and Notice of AGM.</description>
    </item>
    <item>
      <title>4basebio Receives GMP Licence for its UK DNA ...</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/4basebio-receives-gmp-licence-for-its-uk-dna</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/4basebio-receives-gmp-licence-for-its-uk-dna</guid>
      <pubDate>Wed, 02 Apr 2025 06:00:00 GMT</pubDate>
      <description>4basebio Receives GMP Licence for its UK DNA ....</description>
    </item>
    <item>
      <title>RBC Capital Markets initiates research covera...</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/rbc-capital-markets-initiates-research-covera</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/rbc-capital-markets-initiates-research-covera</guid>
      <pubDate>Fri, 14 Mar 2025 07:00:00 GMT</pubDate>
      <description>RBC Capital Markets initiates research covera....</description>
    </item>
    <item>
      <title>Director&apos;s Dealing</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/directors-dealing-4</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/directors-dealing-4</guid>
      <pubDate>Mon, 03 Mar 2025 16:37:00 GMT</pubDate>
      <description>Director&apos;s Dealing.</description>
    </item>
    <item>
      <title>Appointment of Chief Commercial Officer</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/appointment-of-chief-commercial-officer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/appointment-of-chief-commercial-officer-1</guid>
      <pubDate>Wed, 08 Jan 2025 07:00:00 GMT</pubDate>
      <description>Appointment of Chief Commercial Officer.</description>
    </item>
    <item>
      <title>Directorate Change</title>
      <link>https://6ix.com/company/4basebio-uk-societas/news/directorate-change-101</link>
      <guid isPermaLink="true">https://6ix.com/company/4basebio-uk-societas/news/directorate-change-101</guid>
      <pubDate>Tue, 17 Dec 2024 07:00:00 GMT</pubDate>
      <description>Directorate Change.</description>
    </item>
  </channel>
</rss>